B+
Bull case
25%
Probability
Target price
$3.60
+56.2% vs current
OVID
Ovid TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.40
+4.1% vs current
B-
Bear case
25%
Probability
Target price
$1.40
-39.3% vs current
AI sentiment snapshot
Latest data as of 2026-06-20
Recent news sentiment (30D)
+45.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+50.6
Score
AI commentary
Primary-source tone is constructive on pipeline execution and cash runway, but the setup remains a cautious monitoring story, not a broad re-rating thesis. The latest company filing on June 11, 2026 was administrative, recent independent news in the packet is sparse, and the deterministic prior remains negative, so sentiment likely stays tethered to OV329 and OV4071 data timing rather than momentum alone.
RankAlpha Sentiment Codex - 2026-06-20
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-09-30eventOV4071 Phase 1 human data progressionHigh impact
Ovid has already started Phase 1 healthy-volunteer work for OV4071 after regulatory clearance, and the next meaningful checkpoint is an early safety, tolerability, and PK update that shows the KCC2 activator is progressing cleanly in humans [#SEC-8K-2026-03-18] [#PR-EARNINGS-2026-05-12].
2026-12-31eventOV329 move into patient proof-of-concept studiesHigh impact
Management said OV329 showed favorable safety, tolerability, PK, and exposure across dose cohorts and that those data support planned Phase 2 and proof-of-concept work, including focal-onset seizure and PPR-related studies plus expansion into TSC seizures and infantile spasms [#SEC-8K-2026-03-18] [#PR-EARNINGS-2026-05-12].
2027-06-30catalystRunway supports multiple clinical shots on goalMedium impact
Ovid reported $165.6 million of cash, cash equivalents, and marketable securities as of March 31, 2026, excluding $27.3 million received in April 2026 from Series A warrant exercises, reducing near-term financing pressure while the pipeline advances, though not eliminating later dilution risk [#PR-EARNINGS-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-20 • Updated nightlySource: Internal modelMethodology